Stockscreener 앱 받기
2.09
2.20%
0.045
Mei Pharma Inc 주식(MEIP)의 최신 뉴스
MEI Pharma (NASDAQ:MEIP) Earns Buy Rating from Analysts at StockNews.com - Defense World
A new MEI study highlights the importance of micro-entrepreneurs in supplying drinking water to poorer neighbourhoods in Ivory Coast - GlobeNewswire Inc.
10 Best NASDAQ Stocks to Buy According to Billionaires - Insider Monkey
Inside Buffett’s $334B Cash Pile: Get Ready for Berkshire Hathaway Earnings - The Globe and Mail
MEI Pharma (NASDAQ:MEIP) Now Covered by StockNews.com - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
StockNews.com Initiates Coverage on MEI Pharma (NASDAQ:MEIP) - Defense World
Follicular Lymphoma Treatment Market 2034: EMA, PDMA, FDA - openPR.com
Follicular Lymphoma Treatment Market 2034: EMA, PDMA, FDA Approval, Clinical Trials, Medication, Prevalence, Revenue, Statistics and Companies by DelveInsight - The Globe and Mail
Sharp Co. (OTCMKTS:SHCAY) Short Interest Down 25.8% in March - The AM Reporter
11 Best Internet Retail Stocks to Buy According to Analysts - Insider Monkey
Billionaire David Tepper’s Top 10 Stock Picks - Insider Monkey
MEI Pharma (NASDAQ:MEIP) Stock Passes Below Two Hundred Day Moving Average – Here’s What Happened - Defense World
MEI Pharma stock hits 52-week low at $1.83 amid market challenges - Investing.com
MEI Pharma stock hits 52-week low at $1.83 amid market challenges By Investing.com - Investing.com South Africa
MEI Pharma (NASDAQ:MEIP) Coverage Initiated at StockNews.com - Defense World
MEI PHARMA INC- The GF Score's 5 Key Aspects of Analysis - GuruFocus
Follicular Lymphoma Market to Reach New Heights in Growth - openPR.com
Follicular Lymphoma Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Roche, BeiGene, Kite Pharma, Incyte Corp, AstraZeneca, MEI Pharma, Novartis, Innovent Biologics, Regeneron - Barchart.com
Virtu Financial LLC Purchases Shares of 10,744 MEI Pharma, Inc. (NASDAQ:MEIP) - Defense World
MEI Pharma (NASDAQ:MEIP) Now Covered by Analysts at StockNews.com - The AM Reporter
StockNews.com Begins Coverage on MEI Pharma (NASDAQ:MEIP) - Defense World
MEI Pharma stock hits 52-week low at $2.27 amid market challenges - Investing.com Australia
The Radoff-JEC Group Nominates Three Highly Qualified Candidates for Election to the Atea Pharmaceuticals Board of Directors - Business Wire
MEI Pharma (NASDAQ:MEIP) Coverage Initiated by Analysts at StockNews.com - Defense World
MEI Pharma stock hits 52-week low at $2.28 amid market challenges - Investing.com Australia
MEI Pharma stock hits 52-week low at $2.28 amid market challenges By Investing.com - Investing.com South Africa
MEI Pharma, Inc. to Host Earnings Call - ACCESS Newswire
10 Cheap Chinese Stocks to Buy Now - Insider Monkey
11 Best Undervalued Stocks to Invest in Now - Insider Monkey
The Polycythemia Vera Market Landscape Heats Up Amid Rising Competition Among Pharma Companies | DelveInsight - The Malaysian Reserve
C-COM Antenna Receives Eutelsat Type Approval - The Globe and Mail
Marginal Zone Lymphoma Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail
Alarm.com (ALRM) Q4 Earnings: What To Expect - The Globe and Mail
Why Tight Corporate-U.S. Treasury Yield Spreads Signal Good News for Ag Markets Prices - The Globe and Mail
MEI Pharma Reports Increased Losses Amid Strategic Shift - TipRanks
MEI Pharma Reports Second Quarter Fiscal Year 2025 Cash Position - BioSpace
MEI Pharma Inc. (MEIP) reports earnings - Quartz
MEI Pharma, Inc. SEC 10-Q Report - TradingView
MEI Pharma's Financial Update: $23.7M War Chest Fuels Strategic Transformation - Stock Titan
Geriatric Population And Unmet Healthcare Needs Fuel Growth In Acute Myeloid Leukemia Market: A Key Driver ... - WhaTech
Malt Lymphoma Pipeline 2024: Detailed Clinical Trials - openPR
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Receives $43.60 Average Target Price from Analysts - Defense World
No Headlines, No Problem: Why Technical Analysis Still Moves Stocks - The Globe and Mail
Layoff Tracker: Viracta, X4 and BMS Detail Current, Upcoming Cuts - BioSpace
Protein Bar Launch in Convenience Channel, Sending Shares of this MicroCap Higher - The Globe and Mail
3 Easy Ways to Build Up Your Portfolio in 2025 - The Globe and Mail
Scientist pleads guilty to stealing trade secrets for Chinese pharma company - Fox28 Savannah
4.10%
자본화:
|
볼륨(24시간):